Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
What's the recommended schedule for lurbinectedin side effect checks?Pramlintide acetate price?How does trastuzumab emtansine's patent expiry affect drug prices?Patent expiration eu dabrafenib?Guselkumab brand name?
See the DrugPatentWatch profile for eliquis
Yes, Eliquis (apixaban) interacts with aspirin. Both drugs increase bleeding risk—Eliquis as a direct oral anticoagulant (DOAC) inhibits factor Xa to prevent clots, while aspirin inhibits platelet aggregation. Combining them heightens the chance of major bleeding events like gastrointestinal hemorrhage or intracranial bleeding.[1][2] Clinical data from trials like ARISTOTLE show Eliquis alone has lower bleeding rates than warfarin, but adding aspirin (often at 81-325 mg daily for cardiovascular protection) roughly doubles major bleeding risk compared to Eliquis monotherapy.[3] Real-world studies, including a 2023 VA analysis of over 100,000 patients, confirm 1.5-2x higher bleeding rates with dual therapy versus Eliquis alone.[4]
Combination use occurs mainly in patients with atrial fibrillation (AFib) plus coronary artery disease (CAD) or after stenting, where aspirin prevents stent thrombosis. Guidelines from the American College of Cardiology (ACC) recommend "triple therapy" (Eliquis + aspirin + clopidogrel) for only 1-4 weeks post-PCI in high-risk cases, then dropping aspirin to minimize bleeding.[5] Long-term dual therapy (Eliquis + low-dose aspirin) is sometimes continued if clot risk outweighs bleeding risk.
Missing Eliquis increases clot risk—take as soon as remembered unless near next dose. For bleeding, stop both drugs, apply pressure, seek ER care. Reversal agent for Eliquis is andexanet alfa (Andexxa); platelets or FFP don't fully reverse aspirin effects.[2] Inform all providers of combo use; carry a med list. [1]: FDA Eliquis Label [2]: Drugs.com Interaction Checker [3]: NEJM ARISTOTLE Trial [4]: JAMA Network Open VA Study (2023) [5]: ACC/AHA Guideline (2019) [6]: Lancet Meta-Analysis on PPIs [7]: NEJM AUGUSTUS Trial
Other Questions About Eliquis :